DBITE
Live / Applied — Fourth extension granted (statement of use) (as of 14 May 2025)
What this means for you
Not registered yet, but its 31 Mar 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97341385
- Mark type
- Stylized text
- Filed
- 31 Mar 2022
- Published for opposition
- 25 Apr 2023
- Attorney of record
- Elsa D. Lemoine
Goods and services
- Class 005 — Pharmaceuticals: Medicaments, namely, polypeptides, for use in the treatment of tumorous diseases, cancer, allergies, autoimmunity, inflammation, osteoporosis, graft versus host diseases, transplant rejection, cardiovascular diseases, metabolic diseases, neurological diseases, and minimal residual diseases
- Class 009 — Scientific and electric apparatus: Downloadable educational materials, namely, video recordings, books, and printable booklets on therapeutic polypeptides and use thereof
- Class 016 — Paper goods and printed matter: Printed educational materials on therapeutic polypeptides and use thereof; printed educational materials in the field of therapeutic polypeptides and use thereof
- Class 035 — Advertising and business services: Promoting interest, namely, promoting the interests of healthcare practitioners, and promoting awareness, namely, advertising in the nature of promoting the goods of others to healthcare practitioners and the public regarding therapeutic polypeptides and use thereof; promoting education for healthcare professionals on health and medical issues, namely, therapeutic polypeptides and use thereof
- Class 042 — Scientific and technological services: Providing medical and scientific research information regarding therapeutic polypeptides and use thereof; providing a website featuring medical and scientific research information regarding antibody derivatives and use thereof; providing scientific information regarding antibody derivatives and use thereof; providing a website featuring scientific information regarding antibody derivatives and use thereof
Owner
- Amgen Research (Munich) GmbH, Munich, DE
- Amgen Research (Munich) GmbH, Munich, DE
Prosecution history
- 08 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 15 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 May 2025 — SOU EXTENSION 4 GRANTED
- 14 May 2025 — SOU EXTENSION 4 FILED
- 14 May 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Oct 2024 — SOU EXTENSION 3 GRANTED
- 25 Oct 2024 — SOU EXTENSION 3 FILED
- 25 Oct 2024 — SOU TEAS EXTENSION RECEIVED
- 26 Apr 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Apr 2024 — SOU EXTENSION 2 GRANTED
- 25 Apr 2024 — SOU EXTENSION 2 FILED
- 25 Apr 2024 — SOU TEAS EXTENSION RECEIVED
- 01 Dec 2023 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 01 Dec 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED